A routine panel comes back with elevated liver enzymes. When a follow-up ultrasound confirms fat in the liver, the fatty liver disease treatment offered is two sentences: try to lose some weight and come back in six months. There is no plan, no numbers and no follow-up schedule worth the name.
Fatty liver disease reverses when weight falls and insulin sensitivity improves and nothing on the supplement shelf does the work that weight loss, blood sugar control and, where appropriate, GLP-1 therapy now do. The condition, recently renamed metabolic dysfunction-associated steatotic liver disease, is the liver's face of the same metabolic problem that drives prediabetes and heart disease. Treating it as a liver-only issue misses the point and treating it with vague encouragement misses the opportunity.
- Fatty liver is reversible in most cases: roughly 7 percent weight loss reduces liver fat and 10 percent or more can improve inflammation and early scarring.
- No approved drug reverses the common form. Structured weight loss, blood sugar control and exercise carry the evidence.
- GLP-1 medications now have trial evidence for liver benefit in the inflammatory form, working through weight and insulin sensitivity.
- The liver is tracked with enzymes, metabolic markers and imaging in a system that includes HbA1c, ApoB and inflammation, not in isolation.
- The membership is $299 per month with a $598 first charge covering the first two months and prescriptions are billed separately at pharmacy cost.
Why fatty liver is a whole-body problem
The name change matters. The old name, nonalcoholic fatty liver disease, described what the condition was not. The new name, metabolic dysfunction-associated steatotic liver disease, describes what it is: fat accumulating in a liver that is drowning in the same insulin resistance that drives elevated blood sugar, elevated ApoB and chronic inflammation. A person with fatty liver carries elevated cardiovascular risk alongside the liver risk and the two share one root.
That is why we never treat the enzymes alone. Our protocol reads the liver markers beside the full quarterly Biomarker Audit, because the intervention that helps the liver is the same one that helps the pancreas, the vessels and the scale. You can see the full panel in biomarker audits vs standard blood tests.
What the evidence supports
The AASLD practice guidance on fatty liver is blunt and we follow it. Structured weight loss is the primary treatment. The thresholds are concrete:
- About 7 percent of body weight reduces liver fat meaningfully.
- 10 percent or more can improve the inflammatory form and early scarring.
- Resistance training and aerobic activity improve liver fat even without large scale losses.
- Alcohol reduction helps at every stage and abstinence is the target in advanced disease.
A surgical or diet program that produces dramatic short-term loss without a maintenance structure usually produces a rebound that is worse than the starting point. The program that works is boring: adequate protein, resistance training, a calorie target you can actually hold and monitoring every 90 days.
Where GLP-1 therapy fits
For patients with obesity or diabetes, GLP-1 medications have moved from plausible to evidenced. Semaglutide showed resolution of liver inflammation in a meaningful share of patients with the inflammatory form in recent trial data published in 2025 and tirzepatide reduced liver fat in trials. The mechanism is indirect and honest: these medications produce the weight loss and insulin sensitivity improvement that the liver needs and they do it more reliably than willpower alone.
We prescribe branded, FDA-approved products only: Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo (orforglipron). Never compounded GLP-1, under any circumstance, because the compounded versions carry dosing and safety questions the liver cannot afford.
The reversal toolkit, ranked by evidence
| Intervention | Evidence strength | What it does |
|---|---|---|
| Structured weight loss of 7 to 10 percent | Strong | Reduces liver fat, improves inflammation and early fibrosis |
| Blood sugar control | Strong | Treats the root insulin resistance |
| Resistance and aerobic training | Moderate to strong | Improves liver fat independent of scale changes |
| GLP-1 therapy in eligible patients | Growing | Produces the weight loss reliably, with liver benefit in trials |
| Vitamin E and other supplements | Weak to none | Not a substitute for any of the above |
What monitoring actually looks like
A real plan has numbers and a schedule. Ours includes liver enzymes, HbA1c and insulin markers, lipids and ApoB, hs-CRP and the full hormone and thyroid panels, repeated every 90 days through the quarterly Biomarker Audit. Imaging such as a fibrosis score is ordered where findings warrant it, billed at pass-through cost. The point of the cadence is that reversal is visible: enzymes normalize first, then weight and blood sugar trends follow and the plan adjusts against data rather than against hope.
What it costs, stated plainly
The Cardiometabolic Optimization Membership is one flat $299 per month for the clinical relationship. The first charge is $598, one payment at checkout covering the first two months together, including the clinical intake and your first comprehensive Biomarker Audit. From month three it is $299 per month, month to month and you can cancel anytime after the initial commitment.
The medicine is a separate charge, billed directly by the pharmacy at pharmacy cost with zero markup, no molecule upcharge and no dose-escalation fee. One flat fee for the doctor. Zero markup on the medicine. We make money when you get healthier, not when your dose gets stronger. Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. All labs run through the Beluga Health lab network.
The objection we hear most
Why pay for a membership to be told to lose weight? Because the telling is the easy part and the protocol is the part that was missing. The $598 and the quarterly audits buy a physician who reads your panels, a written plan with targets and a schedule and, where appropriate, branded medication at pharmacy cost with no markup. A high-deductible plan with a six-month follow-up is the alternative and you already know how that goes.
If you want a plan with numbers attached, the eligibility assessment is the first step and Cardiometabolic Optimization: the definitive guide explains the full framework.
FAQ
Can fatty liver disease be reversed?
Yes, in most cases. Fat leaves the liver when weight falls and insulin sensitivity improves. A loss of roughly 7 percent of body weight reduces liver fat and a loss of 10 percent or more can improve inflammation and early scarring. The liver is one of the most reversible organs in the metabolic system when the treatment actually targets weight and blood sugar.
What is the best treatment for fatty liver disease?
There is no approved pill for the common form. The best-evidenced treatment is structured weight loss combined with blood sugar control, exercise and alcohol reduction. In patients with obesity or diabetes, GLP-1 medications now have trial evidence showing meaningful liver benefit alongside the weight loss.
Do GLP-1 medications help fatty liver?
Yes. Semaglutide showed liver inflammation improvement in recent trial data in patients with the inflammatory form of fatty liver disease and tirzepatide reduced liver fat in trials. They work through weight loss and improved insulin sensitivity rather than by acting on the liver directly and they are prescribed alongside the same behavioral foundation.
Which supplements actually work for fatty liver?
None have solid outcome evidence and the supplement aisle is the wrong place to spend this problem's budget. Vitamin E has limited evidence in a specific subset and carries its own risks. The honest answer is that the money most people spend on liver supplements is better spent on the weight loss and blood sugar work that actually reverses the condition.
What labs track fatty liver disease?
Liver enzymes such as ALT and AST, along with metabolic markers including HbA1c, fasting insulin, lipids and ApoB. Imaging such as fibrosis scoring or ultrasound tracks the liver itself. Our quarterly Biomarker Audit covers the metabolic side every 90 days so the trend is visible rather than guessed.
Is fatty liver disease serious?
The simple fatty form is common and often quiet, but the inflammatory form can progress to scarring, cirrhosis and liver cancer in a minority of patients and fatty liver is also a marker of whole-body metabolic risk including heart disease. That combination, quiet but consequential, is exactly why it deserves a real plan rather than reassurance.
How much does treatment cost at GoodLife Health?
The membership is $299 per month after a $598 first charge covering the first two months and it includes the quarterly Biomarker Audit and the clinical relationship. Prescriptions are billed separately by the pharmacy at pharmacy cost with zero markup. Labs beyond the quarterly cadence are billed at pass-through cost.
Do I need to stop drinking entirely?
Meaningful alcohol reduction helps at every stage and complete abstinence is advised in the inflammatory or scarring forms. Your physician will set the target based on your specific findings and the honest version is that alcohol works against every other part of the plan.
One last thing
Fatty liver is one of the few diagnoses where the treatment is also the treatment for everything else you are worried about: your blood sugar, your ApoB, your weight, your future. That is rare in medicine and it makes the effort unusually worthwhile. Bring your enzyme results and your last lipid panel to a physician who will build the plan with dates and numbers on it.
Related guides
- A1c and weight loss: how improving blood sugar drives results
- Average weight loss by GLP-1 medication: trial data
- Cardiometabolic optimization: the definitive guide
References
- Semaglutide 2.4 mg once weekly in adults with overweight or obesity and metabolic dysfunction-associated steatohepatitis (ESSENCE, Lancet Gastroenterology & Hepatology). 2025. doi.org/10.1016/S2468-1253(25)00083-500083-5)
- AASLD Practice Guidance on the clinical assessment and management of NAFLD. 2023. doi.org/10.1002/hep.32942